公开(公告)号：US20120213814A1

公开(公告)日：2012-08-23

申请号：US13399654

申请日：2012-02-17

申请人： Takayuki Shiratsuchi ,  Moriya Tsuji

发明人： Takayuki Shiratsuchi ,  Moriya Tsuji

IPC分类号： A61K39/015 ,  A61P37/04 ,  A61P33/06 ,  C12N7/01

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

摘要： The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

摘要翻译： 本公开涉及腺病毒蛋白质修饰以增强对重组腺病毒的转基因的免疫应答并且绕过预先存在的抗腺病毒免疫。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其中重组腺病毒质粒载体包含可操作地连接到异源启动子和修饰的衣壳或核心蛋白的编码疟原虫环子孢子蛋白或其抗原部分的核苷酸序列 其中将疟原虫周围子孢子的免疫原性表位插入或取代至少部分衣壳或核心蛋白。 其它实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 另外的实施方案包括治疗，预防或诊断疟疾的方法，包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

公开(公告)号：US20080199859A1

公开(公告)日：2008-08-21

申请号：US11666056

申请日：2005-10-24

申请人： Toyokazu Seki ,  Takayuki Shiratsuchi ,  Osamu Ogawa ,  Seiji Naito ,  Taiji Tsukamoto ,  Hiroshi Toma ,  Yoshihiko Hirao ,  Susumu Kagawa ,  Yoshiaki Nose ,  Tsuyoshi Nakamura

发明人： Toyokazu Seki ,  Takayuki Shiratsuchi ,  Osamu Ogawa ,  Seiji Naito ,  Taiji Tsukamoto ,  Hiroshi Toma ,  Yoshihiko Hirao ,  Susumu Kagawa ,  Yoshiaki Nose ,  Tsuyoshi Nakamura

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

摘要： The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.

摘要翻译： 本发明提供了对肾细胞癌的IFN治疗作出反应的鉴定标志物及其检测手段。 即，包括从患有肾细胞癌的患者的标本中制备人基因或其互补链的基因组DNA的方法，分析基因组DNA或其互补链的DNA序列，以确定基因组DNA的基因多态性 人类基因，并以多态性为指标，评估IFN治疗对肾细胞癌的肿瘤抑制作用。

公开(公告)号：US09555089B2

公开(公告)日：2017-01-31

申请号：US13399654

申请日：2012-02-17

申请人： Takayuki Shiratsuchi ,  Moriya Tsuji

发明人： Takayuki Shiratsuchi ,  Moriya Tsuji

IPC分类号： A61K39/015 ,  C12N15/861 ,  A61P33/06 ,  C12N7/01 ,  A61K39/00 ,  C07K14/005

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

摘要： The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

摘要翻译： 本公开涉及腺病毒蛋白修饰以增强对重组腺病毒的转基因的免疫应答并且绕过预先存在的抗腺病毒免疫。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其中重组腺病毒质粒载体包含可操作地连接到异源启动子和修饰的衣壳或核心蛋白的编码疟原虫环子孢子蛋白或其抗原部分的核苷酸序列 其中将疟原虫周围子孢子的免疫原性表位插入或取代至少部分衣壳或核心蛋白。 其它实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 另外的实施方案包括治疗，预防或诊断疟疾的方法，包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

公开(公告)号：US07838229B2

公开(公告)日：2010-11-23

申请号：US11666056

申请日：2005-10-24

申请人： Toyokazu Seki ,  Takayuki Shiratsuchi ,  Osamu Ogawa ,  Seiji Naito ,  Taiji Tsukamoto ,  Hiroshi Toma ,  Yoshihiko Hirao ,  Susumu Kagawa ,  Yoshiaki Nose ,  Tsuyoshi Nakamura

发明人： Toyokazu Seki ,  Takayuki Shiratsuchi ,  Osamu Ogawa ,  Seiji Naito ,  Taiji Tsukamoto ,  Hiroshi Toma ,  Yoshihiko Hirao ,  Susumu Kagawa ,  Yoshiaki Nose ,  Tsuyoshi Nakamura

IPC分类号： C07H21/04 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

摘要： The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.

摘要翻译： 本发明提供了对肾细胞癌的IFN治疗作出反应的鉴定标志物及其检测手段。 即，包括从患有肾细胞癌的患者的标本中制备人基因或其互补链的基因组DNA的方法，分析基因组DNA或其互补链的DNA序列，以确定基因组DNA的基因多态性 人类基因，并以多态性为指标，评估IFN治疗对肾细胞癌的肿瘤抑制作用。